Navigation Links
Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
Date:3/18/2009

rmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus. For further information about Idenix, please refer to www.idenix.com.

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward- looking statements can be identified by the use of forward-looking terminology such as "expect," "may," "plans," "anticipates," "preliminary," "will," or similar expressions, or by express or implied statements with respect to the company's clinical development programs or commercialization activities in hepatitis C, or any potential pipeline candidates and expectations with respect to future milestone payments and cash balances at the end of 2009 or beyond. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, clinical trials, including additional data relating to the ongoing clinical trials evaluating its product candidates; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; the company's dependence on third party collaborators, changes in the company's business plan or objectives; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain a
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
5. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
9. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
10. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
11. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... As part of its 2015 growth plan ... and technical service business units, Whitehouse Laboratories is pleased to announce that ... adjacent to the Container Center of Excellence and will be strictly dedicated to basic USP ...
(Date:7/29/2015)... -- Sanofi, a global and diversified ... of 2015. CEO Olivier Brandicourt comments ... different businesses. Watch video interview and ... Topics covered in the interview include:  ... drivers - Diabetes - ...
(Date:7/29/2015)... July 30, 2015 According to a ... Growth, Trends & Forecasts (2015-2020), , published by Mordor Intelligence, ... billion by the end of 2020, with North ... more than 40% of the global market size. The Global ... CAGR of 13.7% during the period of (2015-2020). ...
(Date:7/29/2015)... Japan (Q2 2015: +14% CER / 20% of sales) ... in China , as well as solid contributions from Korea, ... Europe / Middle East / ... in Germany , Turkey and the ... 49% of sales) grew 11%, excluding U.S. HPV sales, on demand across all ...
Breaking Biology Technology:Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10
... SHANGHAI, China, June 10 /Xinhua-PRNewswire/ -- WuXi ... medical device research,and development outsourcing company with ... today that it has signed a new ... http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ), In April 2006, ...
... Completes FDA Submission for Removal of Clinical Hold, ... (OTC Bulletin Board: GNTA) announced that the Company ... from the European,Patent Office for its pipeline product, ... composition of matter for the tesetaxel drug,substance and ...
... technology to, further reduce risk of variant Creutzfeldt-Jakob Disease ... ... - Octapharma sponsoring lunchtime Symposium at meeting to discuss prion ... MONTREAL, Canada and CAMBRIDGE, United Kingdom, June 10,/PRNewswire-FirstCall/ - ProMetic ...
Cached Biology Technology:WuXi PharmaTech (NYSE: WX) Expands Collaboration With AstraZeneca 2Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane 2Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane 3Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane 4ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 2ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 3ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 4ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 5ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 6
(Date:7/21/2015)... , July 21, 2015 Today, ZTE announced ... received as well as expected revenues in 2015 that relate to ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ... a leading smartphone manufacturer in China and ... 02 5 for Axon , ...
(Date:7/13/2015)... JOSE, Calif. , July 13, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... generation touch and display driver integration (TDDI) product ... is the first to combine Synaptics , ... with proven display driver technology developed in the ...
(Date:7/9/2015)... , July 9, 2015  Unchained Labs just ... its acquisition of Avid Nano. Avid Nano designs, ... (DLS) systems.    Also today, Unchained ... and easiest to use protein sizing system. The ... a protein,s hydrodynamic size, size distribution, aggregation population ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... A rat thought extinct for 11 million years and a ... discovered in the Greater Mekong Region of Southeast Asia in ... World Wildlife Fund (WWF). First Contact in ... newly identified by science between 1997 and 2007 which ...
... A newly published genome sequence of a breast ... blueprint involving breaks and fusions of genes and a ... of Medicine in a report that appears online in ... a computer program that has become buggy and transcends ...
... ─ A new study uncovers 11 gene variants ... cardiovascular disease risk: low-density lipoprotein (LDL) cholesterol, high-density ... new opportunities for nutrigenomics researchers looking for links ... and lower chronic disease risk. "Practically all ...
Cached Biology News:Over 1,000 species discovered in the Greater Mekong in past decade 2Breast cancer genome shows evolution, instability of cancer 2Breast cancer genome shows evolution, instability of cancer 3New gene variants present opportunities in nutrigenomics 2
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
... Goat polyclonal to Cholesterol Oxidase ... / Specificity Cross-reacts with bacteria. Not ... Information Cholesterol oxidases exist as both ... are implicated in bacterial pathogenesis. In addition, ...
Anti-ACTH Immunogen: Porcine ACTH conjugated to BSA. Available Date: 38566...
Goat polyclonal to XAGE1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGFGFRRQGEDNT, corresponding to C terminal amino acids 149-160 of Human XAGE1 Entrez Gene ID: 9...
Biology Products: